2 days ago
High Growth Tech Stocks in Europe to Watch for Potential Expansion
The European market has shown resilience with the pan-European STOXX Europe 600 Index ending 0.65% higher, buoyed by easing trade tensions and slowing inflation in key economies, which may prompt further monetary easing by the European Central Bank. In this context of potential expansion and shifting economic policies, high-growth tech stocks become particularly intriguing for investors seeking opportunities that align with evolving market dynamics and technological advancements.
Name
Revenue Growth
Earnings Growth
Growth Rating
Intellego Technologies
30.80%
45.66%
★★★★★★
Archos
21.07%
36.58%
★★★★★★
KebNi
21.51%
66.96%
★★★★★★
Pharma Mar
29.61%
44.92%
★★★★★★
Bonesupport Holding
29.14%
56.14%
★★★★★★
argenx
21.50%
26.61%
★★★★★★
Skolon
31.51%
99.52%
★★★★★★
Xbrane Biopharma
24.95%
56.77%
★★★★★★
Diamyd Medical
86.29%
93.04%
★★★★★★
Elliptic Laboratories
36.33%
78.99%
★★★★★★
Click here to see the full list of 228 stocks from our European High Growth Tech and AI Stocks screener.
Here's a peek at a few of the choices from the screener.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company focused on developing epigenetics-based therapeutics for cancer and CNS disorders, with a market cap of €226.34 million.
Operations: Oryzon Genomics specializes in discovering and developing epigenetics-based therapeutics targeting cancer and CNS disorders.
Oryzon Genomics, a trailblazer in epigenetic therapies, is making significant strides with an impressive 49.3% annual revenue growth forecast. Despite its current unprofitability, the company's strategic focus on R&D (13.26 million EUR allocated to the VANDAM project) underscores its commitment to addressing rare neurodevelopmental disorders and neuroendocrine tumors through precision medicine. The recent 15 million EUR grant for this project enhances Oryzon's potential in pioneering treatments that could revolutionize patient care in these underserved areas. Additionally, their involvement in high-profile clinical trials like the Phase I/II trial of iadademstat for small cell lung cancer further exemplifies their innovative approach within the biotech sector. With expected profitability and earnings growth of 50.17% per annum over the next three years, Oryzon is positioned to leverage its scientific advancements into commercial success.
Click to explore a detailed breakdown of our findings in Oryzon Genomics' health report.
Explore historical data to track Oryzon Genomics' performance over time in our Past section.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Atea ASA is a leading provider of IT infrastructure and related solutions for businesses and public sector organizations across the Nordic countries and Baltic regions, with a market capitalization of NOK16.73 billion.
Operations: Atea ASA generates revenue primarily from its operations in Norway, Sweden, Denmark, Finland, and the Baltics. The highest revenue contribution comes from Sweden at NOK13.06 billion, followed by Norway at NOK9 billion. Group Shared Services account for NOK10.81 billion in costs.
Atea's strategic emphasis on R&D, with a notable 13% of its revenue directed towards innovation, underpins its robust position in the European tech landscape. Despite a challenging year with earnings growth contracting by 8.8%, the company's revenue is still expected to outpace the Norwegian market, growing at 9.4% annually compared to the market's 2.6%. This resilience is further highlighted by Atea's recent dividend affirmation, committing NOK 786 million back to shareholders, showcasing confidence in its financial health and ongoing value creation strategies.
Dive into the specifics of Atea here with our thorough health report.
Examine Atea's past performance report to understand how it has performed in the past.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Paradox Interactive AB (publ) is a company that focuses on developing and publishing strategy and management games for PC and consoles across various global regions, with a market cap of approximately SEK20.90 billion.
Operations: The company generates revenue primarily from its Computer Graphics segment, amounting to SEK2.18 billion. It operates in diverse regions including North and Latin America, Europe, the Middle East, Africa, and the Asia Pacific.
Paradox Interactive, amidst a dynamic European tech landscape, continues to innovate and expand its gaming universe. The company's recent announcement of two new DLC packs for "Across the Obelisk" underscores its commitment to enhancing player experience and broadening content availability across multiple platforms. Strategic alliances like the one seen with Room 8 Group for "Crusader Kings III: Legacy of Persia" not only diversify Paradox's portfolio but also deepen its historical game narratives, reinforcing its niche in strategy games. Financially, Paradox is poised for growth with a revenue increase of 9.3% annually and an earnings forecast growing at 21.5% per year, complemented by a robust R&D investment strategy that ensures continuous innovation and competitiveness in the high-stakes gaming market.
Click here and access our complete health analysis report to understand the dynamics of Paradox Interactive.
Gain insights into Paradox Interactive's historical performance by reviewing our past performance report.
Take a closer look at our European High Growth Tech and AI Stocks list of 228 companies by clicking here.
Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include BME:ORY OB:ATEA and OM:PDX.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
